vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and ENCORE CAPITAL GROUP INC (ECPG). Click either name above to swap in a different company.
ENCORE CAPITAL GROUP INC is the larger business by last-quarter revenue ($473.6M vs $268.1M, roughly 1.8× ACADIA PHARMACEUTICALS INC). ENCORE CAPITAL GROUP INC runs the higher net margin — 16.2% vs 1.4%, a 14.8% gap on every dollar of revenue. On growth, ENCORE CAPITAL GROUP INC posted the faster year-over-year revenue change (78.3% vs 9.7%). Over the past eight quarters, ENCORE CAPITAL GROUP INC's revenue compounded faster (20.1% CAGR vs 5.3%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Encore Capital Group, Inc. is a publicly traded debt buyer based in the United States. The company is headquartered in San Diego, and operates throughout the United States. The firm is a publicly traded NASDAQ Global Select company (ECPG), a component stock of the Russell 2000, the S&P SmallCap 600, and the Wilshire 4500.
ACAD vs ECPG — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $268.1M | $473.6M |
| Net Profit | $3.6M | $76.7M |
| Gross Margin | — | — |
| Operating Margin | -1.7% | 36.6% |
| Net Margin | 1.4% | 16.2% |
| Revenue YoY | 9.7% | 78.3% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.02 | $3.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $268.1M | — | ||
| Q4 25 | $284.0M | $473.6M | ||
| Q3 25 | $278.6M | $460.4M | ||
| Q2 25 | $264.6M | $442.1M | ||
| Q1 25 | $244.3M | $392.8M | ||
| Q4 24 | $259.6M | $265.6M | ||
| Q3 24 | $250.4M | $367.1M | ||
| Q2 24 | $242.0M | $355.3M |
| Q1 26 | $3.6M | — | ||
| Q4 25 | $273.6M | $76.7M | ||
| Q3 25 | $71.8M | $74.7M | ||
| Q2 25 | $26.7M | $58.7M | ||
| Q1 25 | $19.0M | $46.8M | ||
| Q4 24 | $143.7M | — | ||
| Q3 24 | $32.8M | $30.6M | ||
| Q2 24 | $33.4M | $32.2M |
| Q1 26 | — | — | ||
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — |
| Q1 26 | -1.7% | — | ||
| Q4 25 | 6.1% | 36.6% | ||
| Q3 25 | 12.8% | 37.6% | ||
| Q2 25 | 12.2% | 34.1% | ||
| Q1 25 | 7.9% | 32.9% | ||
| Q4 24 | 59.1% | — | ||
| Q3 24 | 12.6% | 28.9% | ||
| Q2 24 | 12.6% | 28.7% |
| Q1 26 | 1.4% | — | ||
| Q4 25 | 96.3% | 16.2% | ||
| Q3 25 | 25.8% | 16.2% | ||
| Q2 25 | 10.1% | 13.3% | ||
| Q1 25 | 7.8% | 11.9% | ||
| Q4 24 | 55.4% | — | ||
| Q3 24 | 13.1% | 8.3% | ||
| Q2 24 | 13.8% | 9.1% |
| Q1 26 | $0.02 | — | ||
| Q4 25 | $1.61 | $3.32 | ||
| Q3 25 | $0.42 | $3.17 | ||
| Q2 25 | $0.16 | $2.49 | ||
| Q1 25 | $0.11 | $1.93 | ||
| Q4 24 | $0.86 | — | ||
| Q3 24 | $0.20 | $1.26 | ||
| Q2 24 | $0.20 | $1.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $156.8M |
| Total DebtLower is stronger | — | $4.0B |
| Stockholders' EquityBook value | — | $976.8M |
| Total Assets | $1.6B | $5.3B |
| Debt / EquityLower = less leverage | — | 4.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $177.7M | $156.8M | ||
| Q3 25 | $258.0M | $172.5M | ||
| Q2 25 | $253.6M | $172.9M | ||
| Q1 25 | $217.7M | $187.1M | ||
| Q4 24 | $319.6M | $199.9M | ||
| Q3 24 | $155.1M | $247.4M | ||
| Q2 24 | $177.1M | $250.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | $4.0B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $3.7B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | $976.8M | ||
| Q3 25 | $917.3M | $952.9M | ||
| Q2 25 | $822.4M | $896.0M | ||
| Q1 25 | $765.2M | $819.1M | ||
| Q4 24 | $732.8M | $767.3M | ||
| Q3 24 | $577.2M | $1.0B | ||
| Q2 24 | $516.7M | $988.1M |
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.6B | $5.3B | ||
| Q3 25 | $1.3B | $5.3B | ||
| Q2 25 | $1.2B | $5.2B | ||
| Q1 25 | $1.1B | $5.0B | ||
| Q4 24 | $1.2B | $4.8B | ||
| Q3 24 | $976.9M | $5.0B | ||
| Q2 24 | $914.1M | $4.8B |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.83× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $153.2M |
| Free Cash FlowOCF − Capex | — | $126.9M |
| FCF MarginFCF / Revenue | — | 26.8% |
| Capex IntensityCapex / Revenue | — | 5.5% |
| Cash ConversionOCF / Net Profit | — | 2.00× |
| TTM Free Cash FlowTrailing 4 quarters | — | $244.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-48.7M | $153.2M | ||
| Q3 25 | $74.3M | $81.6M | ||
| Q2 25 | $64.0M | $9.5M | ||
| Q1 25 | $20.3M | $45.3M | ||
| Q4 24 | $40.4M | $156.2M | ||
| Q3 24 | $63.2M | $45.9M | ||
| Q2 24 | $25.0M | $35.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | $126.9M | ||
| Q3 25 | $73.9M | $75.6M | ||
| Q2 25 | — | $3.2M | ||
| Q1 25 | — | $38.3M | ||
| Q4 24 | — | $127.2M | ||
| Q3 24 | $63.2M | $39.7M | ||
| Q2 24 | — | $28.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 26.8% | ||
| Q3 25 | 26.5% | 16.4% | ||
| Q2 25 | — | 0.7% | ||
| Q1 25 | — | 9.7% | ||
| Q4 24 | — | 47.9% | ||
| Q3 24 | 25.2% | 10.8% | ||
| Q2 24 | — | 8.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 5.5% | ||
| Q3 25 | 0.1% | 1.3% | ||
| Q2 25 | — | 1.4% | ||
| Q1 25 | — | 1.8% | ||
| Q4 24 | — | 10.9% | ||
| Q3 24 | 0.0% | 1.7% | ||
| Q2 24 | — | 2.1% |
| Q1 26 | — | — | ||
| Q4 25 | -0.18× | 2.00× | ||
| Q3 25 | 1.03× | 1.09× | ||
| Q2 25 | 2.40× | 0.16× | ||
| Q1 25 | 1.07× | 0.97× | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | 1.50× | ||
| Q2 24 | 0.75× | 1.11× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
